Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

OTHER 13INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Tumor-Agnostic 1Other hematologic neoplasm 1

Conditions

Lymphoma 2Neoplasms 1Hematologic Neoplasms 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Has results × Ketoconazole × Clear all
NCT01324310 2019-11-25

Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

Celgene

Phase 1 Completed
15 enrolled 21 charts
LymphoidOther hematologic neoplasm

Lymphoma, Hematologic Neoplasms

NCT01454076 2017-11-01

Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

Takeda

Phase 1 Completed
112 enrolled 19 charts
Lymphoid

Lymphoma

NCT01000376 2013-09-23

Evaluating the Pharmacokinetics and Tolerance of Co-administration of Oral Multiple Dose of Ketoconazole and an IV (Bolus) Infusion of Eribulin in Patients With Advanced Solid Tumors

Eisai Inc.

Phase 1 Completed
12 enrolled 9 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡